指南与共识细菌感染、耐药与抗菌药物

欧洲临床微生物学与感染病学会(ESCMID)多耐药革兰阴性杆菌感染治疗指南(欧洲重症医学会认可)

European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
指南 / 共识 · Clin Microbiol Infect · 2021-12-16

ESCMID专家组针对第三代头孢菌素耐药肠杆菌目及碳青霉烯耐药革兰阴性菌的靶向抗生素治疗制定指南,聚焦单药疗效及联合与单药治疗比较。系统评价纳入随机对照试验和观察性研究,以全因死亡率为主要结局,采用GRADE分级证据确定性并给出强或条件(弱)推荐。多数推荐基于极低和低确定性证据。

要点

  • 指南覆盖3GCephRE及碳青霉烯耐药肠杆菌目、铜绿假单胞菌和鲍曼不动杆菌的靶向治疗。
  • 许多比较仅基于高偏倚风险的小型观察性研究,新β-内酰胺/β-内酰胺酶抑制剂证据很少。
  • 所有推荐高度重视抗生素管理,3GCephRE寻求保碳青霉烯方案,新抗生素限用于脓毒症3标准定义的严重感染。

核心结论

  • 指南多数推荐基于极低和低确定性证据,许多抗生素间比较仅来自高偏倚风险的小型观察性研究。
  • 近期获批的新型β-内酰胺/β-内酰胺酶抑制剂对碳青霉烯耐药革兰阴性菌感染效果的证据非常少。
  • 所有推荐均高度重视抗生素管理,3GCephRE寻求保碳青霉烯方案,新抗生素限用于脓毒症3标准定义的严重感染。

研究设计与样本

  • ESCMID召集专家组制定指南,系统评价纳入随机对照试验和观察性研究,比较3GCephRE、碳青霉烯耐药肠杆菌目、碳青霉烯耐药铜绿假单胞菌和碳青霉烯耐药鲍曼不动杆菌感染的靶向抗生素方案。
  • 治疗分类为单个抗生素间头对头比较及单药与联合方案比较,仅纳入定义明确的单药和联合方案;主要结局为全因死亡率(优选30天),次要结局包括临床失败、微生物学失败、耐药发生、复发/再感染、不良事件和住院时长。
  • 所有数据库最后检索于2019年12月,随后针对截至ECCMID 2021的相关研究进行聚焦检索;数据以叙述性方式总结,证据确定性按GRADE推荐分级,推荐强度分为强或条件(弱)。

主要发现

  • 许多抗生素间及单药与联合方案间的比较仅在高偏倚风险的小型观察性研究中评估。
  • 关于近期获批的新型β-内酰胺/β-内酰胺酶抑制剂对碳青霉烯耐药革兰阴性菌感染效果的证据非常少。
  • 大多数推荐基于极低和低确定性证据。

关键数值与推荐

  • 证据确定性按GRADE推荐分级,推荐强度分为强或条件(弱)。
  • 3GCephRE治疗推荐中高度重视抗生素管理,寻求保碳青霉烯方案。
  • 新型抗生素推荐限用于脓毒症3标准定义的严重感染。

临床怎么用

  • 3GCephRE靶向治疗应重视抗生素管理,寻求保碳青霉烯方案。
  • 新型抗生素限用于脓毒症3标准定义的严重感染。
  • 指南按病原体、优选按感染部位审查证据并批判性评价现有研究。

局限性

  • 许多比较仅在高偏倚风险的小型观察性研究中评估。
  • 关于近期获批的新型β-内酰胺/β-内酰胺酶抑制剂对碳青霉烯耐药革兰阴性菌感染效果的证据非常少。
  • 大多数推荐基于极低和低确定性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SCOPE: These ESCMID guidelines address the targeted antibiotic treatment of third-generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem-resistant Gram-negative bacteria, focusing on the effectiveness of individual antibiotics and on combination versus monotherapy. METHODS: An expert panel was convened by ESCMID. A systematic review was performed including randomized controlled trials and observational studies, examining different antibiotic treatment regimens for the targeted treatment of infections caused by the 3GCephRE, carbapenem-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii. Treatments were classified as head-to-head comparisons between individual antibiotics and between monotherapy and combination therapy regimens, including defined monotherapy and combination regimens only. The primary outcome was all-cause mortality, preferably at 30 days and secondary outcomes included clinical failure, microbiological failure, development of resistance, relapse/recurrence, adverse events and length of hospital stay. The last search of all databases was conducted in December 2019, followed by a focused search for relevant studies up until ECCMID 2021. Data were summarized narratively. The certainty of the evidence for each comparison between antibiotics and between monotherapy and combination therapy regimens was classified by the GRADE recommendations. The strength of the recommendations for or against treatments was classified as strong or conditional (weak). RECOMMENDATIONS: The guideline panel reviewed the evidence per pathogen, preferably per site of infection, critically appraising the existing studies. Many of the comparisons were addressed in small observational studies at high risk of bias only. Notably, there was very little evidence on the effects of the new, recently approved, β-lactam/β-lactamase inhibitors on infections caused by carbapenem-resistant Gram-negative bacteria. Most recommendations are based on very-low- and low-certainty evidence. A high value was placed on antibiotic stewardship considerations in all recommendations, searching for carbapenem-sparing options for 3GCephRE and limiting the recommendations of the new antibiotics for severe infections, as defined by the sepsis-3 criteria. Research needs are addressed.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect. 2021. PMID: 34923128. doi:10.1016/j.cmi.2021.11.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。